Systemic Anaplastic Large Cell Lymphoma News and Research

RSS
Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Systemic ALCL is a type of T-cell non-Hodgkin lymphoma that expresses the CD30 antigen. Although standard front-line combination chemotherapy regimens used to treat systemic ALCL often result in long-term remissions and cures, there are limited therapeutic options and a strong unmet medical need for patients with relapsed or refractory disease. SGN-35 has received orphan drug designation for ALCL from both the FDA and the European Medicines Agency.
Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics starts Brentuximab Vedotin retreatment trial

Seattle Genetics starts Brentuximab Vedotin retreatment trial

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics presents new data on antibody-drug conjugate

Seattle Genetics presents new data on antibody-drug conjugate